View Future GrowthiXensor 과거 순이익 실적과거 기준 점검 0/6iXensor은 연평균 8.8%의 비율로 수입이 증가해 온 반면, Medical Equipment 산업은 연평균 5.1%의 비율로 증가했습니다. 매출은 연평균 9.9%의 비율로 감소했습니다.핵심 정보8.78%순이익 성장률16.06%주당순이익(EPS) 성장률Medical Equipment 산업 성장률11.47%매출 성장률-9.94%자기자본이익률-203.36%순이익률-174.69%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Apr 22Full year 2025 earnings released: NT$1.37 loss per share (vs NT$2.05 loss in FY 2024)Full year 2025 results: NT$1.37 loss per share. Revenue: NT$26.9m (up 38% from FY 2024). Net loss: NT$47.0m (flat on FY 2024).Reported Earnings • May 05Full year 2023 earnings released: NT$1.15 loss per share (vs NT$0.09 loss in FY 2022)Full year 2023 results: NT$1.15 loss per share (further deteriorated from NT$0.09 loss in FY 2022). Revenue: NT$20.9m (down 80% from FY 2022). Net loss: NT$63.2m (loss widened NT$58.3m from FY 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 17First half 2022 earnings released: EPS: NT$0.23 (vs NT$0.95 loss in 1H 2021)First half 2022 results: EPS: NT$0.23 (up from NT$0.95 loss in 1H 2021). Revenue: NT$79.3m (up NT$72.1m from 1H 2021). Net income: NT$12.5m (up NT$62.1m from 1H 2021). Profit margin: 16% (up from net loss in 1H 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • May 02Full year 2021 earnings released: NT$1.40 loss per share (vs NT$1.56 loss in FY 2020)Full year 2021 results: NT$1.40 loss per share (up from NT$1.56 loss in FY 2020). Revenue: NT$24.8m (up 56% from FY 2020). Net loss: NT$73.1m (loss narrowed 4.6% from FY 2020).모든 업데이트 보기Recent updatesNew Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$37m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$37m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Revenue is less than US$1m (NT$27m revenue, or US$852k). Market cap is less than US$10m (NT$276.2m market cap, or US$8.76m).Reported Earnings • Apr 22Full year 2025 earnings released: NT$1.37 loss per share (vs NT$2.05 loss in FY 2024)Full year 2025 results: NT$1.37 loss per share. Revenue: NT$26.9m (up 38% from FY 2024). Net loss: NT$47.0m (flat on FY 2024).공시 • Mar 03iXensor Co., Ltd., Annual General Meeting, May 20, 2026iXensor Co., Ltd., Annual General Meeting, May 20, 2026, at 10:00 Taipei Standard Time. Location: 1 floor no,399, jui kuang rd., neihu district, taipei city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (33% average weekly change). Negative equity (-NT$16m). Revenue is less than US$1m (NT$25m revenue, or US$784k). Market cap is less than US$10m (NT$239.2m market cap, or US$7.62m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Negative equity (-NT$16m). Revenue is less than US$1m (NT$25m revenue, or US$784k). Minor Risk Market cap is less than US$100m (NT$352.2m market cap, or US$11.2m).New Risk • Aug 17New major risk - Negative shareholders equityThe company has negative equity. Total equity: -NT$16m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-NT$16m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$25m revenue, or US$818k). Market cap is less than US$10m (NT$233.3m market cap, or US$7.77m).공시 • Mar 07iXensor Co., Ltd., Annual General Meeting, May 20, 2025iXensor Co., Ltd., Annual General Meeting, May 20, 2025, at 10:00 Taipei Standard Time. Location: 1 floor no,399, jui kuang rd., neihu district, taipei city TaiwanNew Risk • Feb 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-NT$10m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$17m revenue, or US$514k). Market cap is less than US$10m (NT$197.8m market cap, or US$6.01m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-NT$10m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$17m revenue, or US$513k). Market cap is less than US$10m (NT$210.1m market cap, or US$6.37m).New Risk • Jan 02New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 40% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-NT$10m). Revenue is less than US$1m (NT$17m revenue, or US$514k). Market cap is less than US$10m (NT$172.1m market cap, or US$5.23m). Minor Risk Shareholders have been diluted in the past year (40% increase in shares outstanding).New Risk • Aug 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -NT$10m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-NT$10m). Revenue is less than US$1m (NT$17m revenue, or US$525k). Market cap is less than US$10m (NT$230.4m market cap, or US$7.15m).New Risk • May 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$48m free cash flow). Revenue is less than US$1m (NT$21m revenue, or US$644k). Market cap is less than US$10m (NT$319.8m market cap, or US$9.86m). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).New Risk • May 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$307.2m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$48m free cash flow). Revenue is less than US$1m (NT$21m revenue, or US$645k). Market cap is less than US$10m (NT$307.2m market cap, or US$9.48m).Reported Earnings • May 05Full year 2023 earnings released: NT$1.15 loss per share (vs NT$0.09 loss in FY 2022)Full year 2023 results: NT$1.15 loss per share (further deteriorated from NT$0.09 loss in FY 2022). Revenue: NT$20.9m (down 80% from FY 2022). Net loss: NT$63.2m (loss widened NT$58.3m from FY 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.공시 • Mar 19iXensor Co., Ltd., Annual General Meeting, Jun 03, 2024iXensor Co., Ltd., Annual General Meeting, Jun 03, 2024.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$450.4m market cap, or US$14.2m).New Risk • Nov 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Minor Risks Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$510.7m market cap, or US$16.2m).New Risk • Aug 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Minor Risks Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$551.3m market cap, or US$17.2m).Reported Earnings • Aug 17First half 2022 earnings released: EPS: NT$0.23 (vs NT$0.95 loss in 1H 2021)First half 2022 results: EPS: NT$0.23 (up from NT$0.95 loss in 1H 2021). Revenue: NT$79.3m (up NT$72.1m from 1H 2021). Net income: NT$12.5m (up NT$62.1m from 1H 2021). Profit margin: 16% (up from net loss in 1H 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • May 02Full year 2021 earnings released: NT$1.40 loss per share (vs NT$1.56 loss in FY 2020)Full year 2021 results: NT$1.40 loss per share (up from NT$1.56 loss in FY 2020). Revenue: NT$24.8m (up 56% from FY 2020). Net loss: NT$73.1m (loss narrowed 4.6% from FY 2020).공시 • Apr 16iXensor Co., Ltd., Annual General Meeting, Jun 30, 2022iXensor Co., Ltd., Annual General Meeting, Jun 30, 2022.공시 • Dec 23iXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other Key Variants of ConcerniXensor Co., Ltd. declared that its computer vision-powered PixoTest® COVID-19 Antigen Test effectively detects all major SARS-CoV-2 variants including Omicron (B.1.1.529) after completing two validation studies. In response to emerging new waves of the COVID-19 pandemic caused by Omicron across the globe, iXensor has conducted in-silico analysis followed by a laboratory validation using the recombinant protein of the Omicron variant. The in-silico study evaluated the amino acid sequences of N protein wild type and the Omicron variant (P13L, E31del, R32del, S33del, R203K, G204R), concluding that Omicron is detectable by PixoTest® COVID-19 Antigen Test. Furthermore, in the recombinant protein study, PixoTest® achieves the same limit of detection (0.25ng/ml) on those variants of concern as on the original wild type of SARS-CoV-2 used as a control. Both study results affirm that the PixoTest® COVID-19 Antigen Test can detect the latest Omicron variant effectively in addition to the previous confirmation on SARS-CoV-2 Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2). Most importantly, the sensitivity of PixoTest® COVID-19 Antigen Test is not affected by the Omicron and other Variants of Concern.분석 기사 • Mar 24Will iXensor (GTSM:6734) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is New 90 Day High Low • Feb 27New 90-day low: NT$19.05The company is down 3.0% from its price of NT$19.70 on 27 November 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 4.0% over the same period.분석 기사 • Dec 10Is iXensor (GTSM:6734) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...Is New 90 Day High Low • Nov 04New 90-day low: NT$19.45The company is down 10.0% from its price of NT$21.50 on 06 August 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 12% over the same period.매출 및 비용 세부 내역iXensor가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TPEX:6734 매출, 비용 및 순이익 (TWD Millions)날짜매출순이익일반관리비연구개발비31 Dec 2527-47352730 Sep 2526-46312730 Jun 2525-45262731 Mar 2522-46262731 Dec 2419-47262630 Sep 2418-52292630 Jun 2417-57332631 Mar 2419-60352631 Dec 2321-63382630 Sep 2329-57382630 Jun 2337-52382631 Mar 2371-28392731 Dec 22105-5402830 Sep 22101-8412730 Jun 2297-11422631 Mar 2261-42403731 Dec 2125-73394730 Sep 2119-81415230 Jun 2114-90435631 Mar 2115-83464631 Dec 2016-77483630 Sep 2019-88603730 Jun 2022-99713931 Mar 2026-102734031 Dec 1930-105764230 Sep 1927-103664730 Jun 1924-101575131 Mar 1918-104555431 Dec 1811-108535731 Dec 1715-108487031 Dec 160-953274양질의 수익: 6734 은(는) 현재 수익성이 없습니다.이익 마진 증가: 6734는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 6734는 수익성이 없지만 지난 5년 동안 연평균 8.8%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 6734의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 6734은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(-3.4%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 6734는 현재 수익성이 없으므로 자본 수익률이 음수(-203.36%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/06 23:27종가2026/07/06 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스iXensor Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Apr 22Full year 2025 earnings released: NT$1.37 loss per share (vs NT$2.05 loss in FY 2024)Full year 2025 results: NT$1.37 loss per share. Revenue: NT$26.9m (up 38% from FY 2024). Net loss: NT$47.0m (flat on FY 2024).
Reported Earnings • May 05Full year 2023 earnings released: NT$1.15 loss per share (vs NT$0.09 loss in FY 2022)Full year 2023 results: NT$1.15 loss per share (further deteriorated from NT$0.09 loss in FY 2022). Revenue: NT$20.9m (down 80% from FY 2022). Net loss: NT$63.2m (loss widened NT$58.3m from FY 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 17First half 2022 earnings released: EPS: NT$0.23 (vs NT$0.95 loss in 1H 2021)First half 2022 results: EPS: NT$0.23 (up from NT$0.95 loss in 1H 2021). Revenue: NT$79.3m (up NT$72.1m from 1H 2021). Net income: NT$12.5m (up NT$62.1m from 1H 2021). Profit margin: 16% (up from net loss in 1H 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • May 02Full year 2021 earnings released: NT$1.40 loss per share (vs NT$1.56 loss in FY 2020)Full year 2021 results: NT$1.40 loss per share (up from NT$1.56 loss in FY 2020). Revenue: NT$24.8m (up 56% from FY 2020). Net loss: NT$73.1m (loss narrowed 4.6% from FY 2020).
New Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$37m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$37m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Revenue is less than US$1m (NT$27m revenue, or US$852k). Market cap is less than US$10m (NT$276.2m market cap, or US$8.76m).
Reported Earnings • Apr 22Full year 2025 earnings released: NT$1.37 loss per share (vs NT$2.05 loss in FY 2024)Full year 2025 results: NT$1.37 loss per share. Revenue: NT$26.9m (up 38% from FY 2024). Net loss: NT$47.0m (flat on FY 2024).
공시 • Mar 03iXensor Co., Ltd., Annual General Meeting, May 20, 2026iXensor Co., Ltd., Annual General Meeting, May 20, 2026, at 10:00 Taipei Standard Time. Location: 1 floor no,399, jui kuang rd., neihu district, taipei city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (33% average weekly change). Negative equity (-NT$16m). Revenue is less than US$1m (NT$25m revenue, or US$784k). Market cap is less than US$10m (NT$239.2m market cap, or US$7.62m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Negative equity (-NT$16m). Revenue is less than US$1m (NT$25m revenue, or US$784k). Minor Risk Market cap is less than US$100m (NT$352.2m market cap, or US$11.2m).
New Risk • Aug 17New major risk - Negative shareholders equityThe company has negative equity. Total equity: -NT$16m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-NT$16m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$25m revenue, or US$818k). Market cap is less than US$10m (NT$233.3m market cap, or US$7.77m).
공시 • Mar 07iXensor Co., Ltd., Annual General Meeting, May 20, 2025iXensor Co., Ltd., Annual General Meeting, May 20, 2025, at 10:00 Taipei Standard Time. Location: 1 floor no,399, jui kuang rd., neihu district, taipei city Taiwan
New Risk • Feb 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-NT$10m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$17m revenue, or US$514k). Market cap is less than US$10m (NT$197.8m market cap, or US$6.01m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-NT$10m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$17m revenue, or US$513k). Market cap is less than US$10m (NT$210.1m market cap, or US$6.37m).
New Risk • Jan 02New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 40% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-NT$10m). Revenue is less than US$1m (NT$17m revenue, or US$514k). Market cap is less than US$10m (NT$172.1m market cap, or US$5.23m). Minor Risk Shareholders have been diluted in the past year (40% increase in shares outstanding).
New Risk • Aug 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -NT$10m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-NT$10m). Revenue is less than US$1m (NT$17m revenue, or US$525k). Market cap is less than US$10m (NT$230.4m market cap, or US$7.15m).
New Risk • May 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$48m free cash flow). Revenue is less than US$1m (NT$21m revenue, or US$644k). Market cap is less than US$10m (NT$319.8m market cap, or US$9.86m). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
New Risk • May 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$307.2m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$48m free cash flow). Revenue is less than US$1m (NT$21m revenue, or US$645k). Market cap is less than US$10m (NT$307.2m market cap, or US$9.48m).
Reported Earnings • May 05Full year 2023 earnings released: NT$1.15 loss per share (vs NT$0.09 loss in FY 2022)Full year 2023 results: NT$1.15 loss per share (further deteriorated from NT$0.09 loss in FY 2022). Revenue: NT$20.9m (down 80% from FY 2022). Net loss: NT$63.2m (loss widened NT$58.3m from FY 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
공시 • Mar 19iXensor Co., Ltd., Annual General Meeting, Jun 03, 2024iXensor Co., Ltd., Annual General Meeting, Jun 03, 2024.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$450.4m market cap, or US$14.2m).
New Risk • Nov 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Minor Risks Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$510.7m market cap, or US$16.2m).
New Risk • Aug 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Minor Risks Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$551.3m market cap, or US$17.2m).
Reported Earnings • Aug 17First half 2022 earnings released: EPS: NT$0.23 (vs NT$0.95 loss in 1H 2021)First half 2022 results: EPS: NT$0.23 (up from NT$0.95 loss in 1H 2021). Revenue: NT$79.3m (up NT$72.1m from 1H 2021). Net income: NT$12.5m (up NT$62.1m from 1H 2021). Profit margin: 16% (up from net loss in 1H 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • May 02Full year 2021 earnings released: NT$1.40 loss per share (vs NT$1.56 loss in FY 2020)Full year 2021 results: NT$1.40 loss per share (up from NT$1.56 loss in FY 2020). Revenue: NT$24.8m (up 56% from FY 2020). Net loss: NT$73.1m (loss narrowed 4.6% from FY 2020).
공시 • Apr 16iXensor Co., Ltd., Annual General Meeting, Jun 30, 2022iXensor Co., Ltd., Annual General Meeting, Jun 30, 2022.
공시 • Dec 23iXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other Key Variants of ConcerniXensor Co., Ltd. declared that its computer vision-powered PixoTest® COVID-19 Antigen Test effectively detects all major SARS-CoV-2 variants including Omicron (B.1.1.529) after completing two validation studies. In response to emerging new waves of the COVID-19 pandemic caused by Omicron across the globe, iXensor has conducted in-silico analysis followed by a laboratory validation using the recombinant protein of the Omicron variant. The in-silico study evaluated the amino acid sequences of N protein wild type and the Omicron variant (P13L, E31del, R32del, S33del, R203K, G204R), concluding that Omicron is detectable by PixoTest® COVID-19 Antigen Test. Furthermore, in the recombinant protein study, PixoTest® achieves the same limit of detection (0.25ng/ml) on those variants of concern as on the original wild type of SARS-CoV-2 used as a control. Both study results affirm that the PixoTest® COVID-19 Antigen Test can detect the latest Omicron variant effectively in addition to the previous confirmation on SARS-CoV-2 Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2). Most importantly, the sensitivity of PixoTest® COVID-19 Antigen Test is not affected by the Omicron and other Variants of Concern.
분석 기사 • Mar 24Will iXensor (GTSM:6734) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is New 90 Day High Low • Feb 27New 90-day low: NT$19.05The company is down 3.0% from its price of NT$19.70 on 27 November 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 4.0% over the same period.
분석 기사 • Dec 10Is iXensor (GTSM:6734) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...
Is New 90 Day High Low • Nov 04New 90-day low: NT$19.45The company is down 10.0% from its price of NT$21.50 on 06 August 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 12% over the same period.